Actinium Expands Clinical Leadership Team to Support Key Development Programs for Iomab-B and Actimab-A
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced a broad senior level expansion of its clinical organization
NEW YORK, Oct. 27, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced a broad senior level expansion of its clinical organization. These key hires strengthen the Company's expertise in hematological malignancies, bone marrow transplant (BMT) and radiation sciences as well its operational capabilities. The addition of Madhuri Vusirikala, MD, Vice President of Clinical Development, BMT and Cellular Therapy, and Akash Nahar, MD, Vice President of Clinical Development, are complemented by the deep nuclear medicine and radiation science expertise with Patrik Brodin, Ph.D., Vice President of Radiation Sciences. Elaina Haeuber, Vice President, Head of Clinical Operations, will lead the clinical operations organization to further support the Company's clinical development plans for its pipeline products including Iomab-B and Actimab-A.
